Business Wire - The global leader in news distribution
Updated: 19 min 56 sec ago
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BIOAF&src=ctag" target="_blank"gt;$BIOAFlt;/agt; lt;a href="https://twitter.com/hashtag/BBB?src=hash" target="_blank"gt;#BBBlt;/agt;--Bioasis announces the appointment of Christine Antalik as chief financial officer.
LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, today announced that Adam B. Raff has been appointed as Director and Medical Advisor in Translational Medicine as of January 28, 2019. Adam Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine. Adam Raff is a Doctor of Medicine (Hons) and holds a Doctorate in Philosophy in Systems Biology and Disease from the University of Sou
SAN DIEGO--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24RMD&src=ctag" target="_blank"gt;$RMDlt;/agt; lt;a href="https://twitter.com/hashtag/COPD?src=hash" target="_blank"gt;#COPDlt;/agt;--ResMed's Mobi portable oxygen concentrator, part of its growing COPD product portfolio, offers an optimal balance of oxygen, battery life and weight.
Introducing ZYUS Life Sciences Inc., The Next Global Leader in Phyto-Therapeutics and Medical Cannabis Derivative Products
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Introducing ZYUS - The Next Global Leader in Phyto-Therapeutics and Medical Cannabis Derived Products
Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BIOAF&src=ctag" target="_blank"gt;$BIOAFlt;/agt; lt;a href="https://twitter.com/hashtag/BBB?src=hash" target="_blank"gt;#BBBlt;/agt;--Bioasis announces agreement with leading pharmaceutical company for pre-clinical research using the xB³ platform technology.
Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer
BOSTON & BURNABY, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/RNA?src=hash" target="_blank"gt;#RNAlt;/agt;--Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019. “With our clinical, preclinical, and business development achievements in 2018, along with a robust balance sheet, we believe we are in a strong position to continue delivering on our corporate objectives in 2019 and beyond,” said Ali Tehrani, Ph.D.,
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary. The protocol for the Phase II clinical trial of pembrolizumab (Keytruda®) in combination with the AE37 Peptide Vaccine in patients with metastatic triple negative breast cancer is under review at the Institutional Review Board (IRB) with oversight of this NSAB
TORONTO--(BUSINESS WIRE)--Grey Wolf Animal Health acquires Veterinary Healthcare Solutions. This combination creates a national presence across Canada and accelerates growth.
HOUSTON--(BUSINESS WIRE)--Total Safety, the world’s leading provider of integrated safety services, announced today that it has strengthened its Canadian presence by acquiring Vantage Safety Services. Based in Clairmont, Alberta, Vantage Safety Services is a full-service industrial safety company providing services to all segments of the oil and gas industry. This acquisition continues Total Safety’s expansion and commitment to the Canadian market. It expands the company’s presence in the Grand
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCMKTS:GNBT) today announced that its partially, soon to be fully-owned subsidiary, Olaregen Therapeutix, Inc. has signed critical manufacturing agreements for Excellagen® with Collagen Solutions, a highly-regarded supplier of medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine applications, and with Berkshire Sterile Manufacturing (BSM), a state-of-the art, GMP fill/finish manufa
BOSTON & BURNABY, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Genevant announced today that its President & CEO Dr. Bo Rode Hansen will present a corporate update at the Biotech Showcase 2019.
AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AVID100?src=hash" target="_blank"gt;#AVID100lt;/agt;--Forbius, a clinical-stage company developing biologics for the treatment of fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Mr. Tikhomirov’s presentation will take place Wednesday, January 9th at 11:30 am PST in Elizabethan D at the Westin St. Francis Hotel in San Francisco. About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer Forbi
Novanta to Present at the CJS Securities 19th Annual “New Ideas for the New Year” Institutional Investor Conference on Wednesday, January 9, 2019
BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the CJS Securities 19th Annual “New Ideas for the New Year” Institutional Investor Conference on Wednesday, January 9, 2019, in New York, NY. About Novanta Novanta is a leading global supplier of
TORONTO--(BUSINESS WIRE)--DNA tests are backbone of the emerging personalized health industry. As research develops, scientists discover more and more information that could be derived from DNA beyond ancestry. The DNA Co. has developed the most advanced functional genomics test in the world that may be able to tell you whether you may be a candidate for certain diseases such as diabetes and prostate cancer. The DNA Company has partnered up with award winning video production company, SPG Media
QUEBEC--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announced that its Annual General Shareholders’ Meeting will be held on Tuesday, January 29, 2019 at 15:30 p.m. EST at Château Bonne Entente, 3400 Chemin Sainte-Foy, City of Québec, Québec. Devonian also announced that it has set Monday, December
SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. GVHD occurs when the transplanted donor cells a
VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cancergenomics?src=hash" target="_blank"gt;#cancergenomicslt;/agt;--Contextual Genomics Inc., a leading Canadian cancer genomics company headquartered in Vancouver, Canada, announces that it has completed development of two new products: (i) an improved version of its FIND ITTM hotspot panel for detection of genomic mutations in solid tumour cancers, and (ii) its FOLLOW ITTM hotspot panel for detection of the same genomic mutations in blood plasma. Contextual Genomics’ FIND ITTM panel, a proprietary molecular hotspo
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archiv
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises